PTB
MCID: PLM001
MIFTS: 73

Pulmonary Tuberculosis (PTB)

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Tuberculosis

MalaCards integrated aliases for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 15
Tuberculosis, Pulmonary 76 44 73
Tuberculosis Pulmonary 55
Ptb 48

Classifications:



External Ids:

Disease Ontology 12 DOID:2957
ICD10 33 A15 A15.0
ICD9CM 35 011 011.9 011.90
MeSH 44 D014397
NCIt 50 C26899
SNOMED-CT 68 81483001
UMLS 73 C0041327

Summaries for Pulmonary Tuberculosis

Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to miliary tuberculosis and pneumonia, and has symptoms including fever, cough and pleural effusion. An important gene associated with Pulmonary Tuberculosis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Priftin and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis... more...

Related Diseases for Pulmonary Tuberculosis

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 504)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 31.7 ADA IFNG IL12RB1 TNF
2 pneumonia 30.7 IL10 MBL2 TLR2 TLR9 TNF
3 lung disease 30.4 IL10 MBL2 TLR2 TLR9 TNF
4 pleurisy 30.4 ADA IFNG IL2 TNF
5 human immunodeficiency virus infectious disease 30.3 IFNG IL10 IL2 TLR9 TNF
6 aspergillosis 30.2 IFNG IL10 IL4 MBL2 TLR2 TLR9
7 arthritis 30.2 HLA-DRB1 IFNG IL10 IL18 TNF
8 nontuberculous mycobacterial lung disease 30.2 HLA-DRB1 SLC11A1 TLR2 TNF
9 invasive aspergillosis 30.1 IFNG MBL2 TLR2 TLR9
10 panuveitis 30.1 HLA-DRB1 IL10 TNF
11 pulmonary sarcoidosis 30.1 IFNG IL18 IL2 TNF
12 mouth disease 30.0 IFNG IL10 TLR9 TNF VDR
13 mycobacterium fortuitum 30.0 IFNGR1 IL12RB1
14 tuberculous meningitis 30.0 ADA NAT2 TLR2 TNF
15 human immunodeficiency virus type 1 30.0 ADA IFNG IL10 IL2 TNF
16 tuberculous peritonitis 30.0 ADA IFNG TNF
17 oral tuberculosis 30.0 IL2 TNF
18 multidrug-resistant tuberculosis 30.0 IL10 INHA SLC11A1 TNF VDR
19 meningitis 30.0 ADA IFNG IL10 MBL2 TLR2 TLR9
20 paracoccidioidomycosis 29.9 IFNG IL10 IL2 IL4 TLR2 TNF
21 peritonitis 29.9 ADA IL10 TLR2 TNF
22 bronchiolitis obliterans 29.9 IFNG IL10 TNF
23 cryptococcosis 29.9 IFNG IL4 MBL2 TLR9
24 endocarditis 29.9 IL10 TLR2 TNF
25 neuritis 29.9 IFNG IL4 TNF
26 herpes zoster 29.9 IFNG IL10 IL2
27 bronchial disease 29.9 IFNGR1 IL10 IL4 TLR9 TNF
28 melioidosis 29.8 IFNG IL10 IL18 TLR2 TNF
29 pericarditis 29.8 ADA IFNG TNF
30 sarcoidosis 1 29.8 HLA-DRB1 IFNG IL12RB1 IL18 IL2 SLC11A1
31 aplastic anemia 29.7 HLA-DRB1 IFNG IL2 IL4 TNF
32 pulmonary fibrosis, idiopathic 29.7 IFNG IL18 TLR9 TNF
33 allergic rhinitis 29.7 IFNG IL10 IL18 IL4
34 acquired immunodeficiency syndrome 29.7 IFNG IL10 IL2 TNF
35 viral infectious disease 29.7 IFNG IL10 IL2 IL4 TLR9 TNF
36 rheumatoid arthritis 29.7 HLA-DRB1 IFNG IL10 IL18 IL2 IL4
37 dermatitis 29.6 IFNG IL18 IL4 TLR9
38 lymphadenitis 29.6 IFNG IFNGR1 IL10 IL12RB1 IL18 SLC11A1
39 interstitial lung disease 29.6 IFNG IL10 IL4 TNF
40 otitis media 29.6 IL10 IL4 MBL2 TLR2 TNF
41 pleural tuberculosis 29.6 ADA IFNG IL18 TNF
42 bronchiolitis 29.6 IFNG IL10 IL4 TLR9 TNF
43 visceral leishmaniasis 29.6 IFNG IL10 IL2 IL4 SLC11A1 TLR2
44 asthma 29.6 HLA-DRB1 IFNG IL10 IL18 IL4 TLR9
45 lepromatous leprosy 29.5 IFNG IFNGR1 IL10 IL12RB1 IL2 TLR2
46 measles 29.5 IFNG IL2 IL4 TLR2
47 diabetes mellitus, insulin-dependent 29.5 HLA-DRB1 IFNG IL10 IL4 VDR
48 leishmaniasis 29.5 HLA-DRB1 IFNG IFNGR1 IL10 IL2 IL4
49 extrapulmonary tuberculosis 29.5 ADA IFNG IL10 MBL2 P2RX7 SLC11A1
50 crohn's disease 29.5 HP IL10 SLC11A1 TLR9 TNF

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis

Symptoms & Phenotypes for Pulmonary Tuberculosis

Symptoms:

12
  • fever
  • cough
  • pleural effusion
  • fibrosis
  • difficulty in breathing
  • inflammatory infiltrations
  • formation of tubercles
  • caseation

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 ADA HP IFNG IFNGR1 IL10 IL12RB1
2 homeostasis/metabolism MP:0005376 10.41 ADA HP IFNG IFNGR1 IL10 IL12RB1
3 immune system MP:0005387 10.39 ADA HP IFNG IFNGR1 IL10 IL12RB1
4 cellular MP:0005384 10.36 ADA HP IFNG IFNGR1 IL10 IL18
5 digestive/alimentary MP:0005381 10.35 ADA IFNG IFNGR1 IL10 IL18 IL2
6 cardiovascular system MP:0005385 10.34 ADA HP IFNG IFNGR1 IL10 IL18
7 behavior/neurological MP:0005386 10.31 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
8 growth/size/body region MP:0005378 10.29 ADA IFNG IL10 IL12RB1 IL18 IL2
9 endocrine/exocrine gland MP:0005379 10.22 ADA IFNG IFNGR1 IL10 IL2 IL4
10 mortality/aging MP:0010768 10.21 ADA HP IFNG IFNGR1 IL10 IL18
11 liver/biliary system MP:0005370 10.1 ADA HP IFNG IFNGR1 IL10 IL2
12 integument MP:0010771 10.09 IFNG IFNGR1 IL10 IL18 IL4 P2RX7
13 neoplasm MP:0002006 9.97 HP IFNG IFNGR1 IL10 IL2 INHA
14 renal/urinary system MP:0005367 9.91 ADA HP IFNG IFNGR1 IL4 MBL2
15 reproductive system MP:0005389 9.85 ADA IFNG IFNGR1 IL10 IL2 IL4
16 respiratory system MP:0005388 9.5 ADA IFNG IL10 IL2 IL4 TLR2
17 skeleton MP:0005390 9.32 ADA IFNG IFNGR1 IL10 IL4 INHA

Drugs & Therapeutics for Pulmonary Tuberculosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Priftin 18 RIFAPENTINE Hoechst Marion Roussel June 1998

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 288)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
2
Ethambutol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 74-55-5 3279 14052
3
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
4
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 57-92-1 19649
5
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 98-96-4 1046
6 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 979-32-8
7
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
8
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 13292-46-1 5458213 5381226
9
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1 28014-46-2
10
Rifabutin Approved, Investigational Phase 4,Phase 2,Not Applicable 72559-06-9 6323490
11
Isoniazid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-85-3 3767
12
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
13
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
14
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100986-85-4 149096
15
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82419-36-1 4583
16
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
18
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 67-97-0 5280795 6221
19 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1
24 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
31 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2,Phase 1
32 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Antitubercular Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Calciferol Phase 4,Phase 3,Phase 2,Not Applicable
36 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Calcium, Dietary Phase 4,Phase 3
38 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Ergocalciferols Phase 4,Phase 3,Phase 2,Not Applicable
40 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Vitamin D2 Phase 4,Phase 3,Phase 2,Not Applicable
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
48
Zinc Approved, Investigational Phase 3 7440-66-6
49
Gatifloxacin Approved, Investigational Phase 3,Phase 1,Phase 2 112811-59-3 5379
50
Emtricitabine Approved, Investigational Phase 3,Phase 2,Phase 1 143491-57-0 60877

Interventional clinical trials:

(show top 50) (show all 255)
# Name Status NCT ID Phase Drugs
1 Research on New Regimens for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
2 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Unknown status NCT02169570 Phase 4
3 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
4 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis Unknown status NCT02464683 Phase 4
5 Simple Verbal Intervention for Adequately Collecting Sputum Unknown status NCT01135043 Phase 4
6 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
7 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
8 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4 Levofloxacin
9 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis Completed NCT00939419 Phase 4
10 Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis Recruiting NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
11 Pilot Clinical Trial of PRS TB Regimen I - Phase II Recruiting NCT03561753 Phase 4 Group A (the standard 2HRZE/4HR regimen);Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
12 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation Active, not recruiting NCT02231229 Phase 4 conventional therapy
13 Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis Unknown status NCT02467608 Phase 2, Phase 3 Isoniazid with HUEXC030 and RZE;HRZE
14 Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3 Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
15 Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients Unknown status NCT00698386 Phase 3
16 Pulmonary Tuberculosis and Vitamin D Unknown status NCT00507000 Phase 3 Cholecalciferol;Lactose granules
17 A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3 Gatifloxacin combined regimen
18 Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Unknown status NCT01398618 Phase 3 4-month rifampin vs. 9-month isoniazid
19 L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) Completed NCT00677339 Phase 3 L-arginine;Vitamin D;Placebo L-arginine;Placebo Vitamin D
20 Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis Completed NCT00864383 Phase 3 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
21 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
22 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
23 Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis Completed NCT00801606 Phase 3 Zinc;Micronutrient without zinc;Micronutrient with zinc;Placebo
24 A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients Completed NCT00366470 Phase 3 A. 100,000 IU Cholecalciferol per dose of 3.3ml
25 Nutrition, Diabetes and Pulmonary TB/HIV Completed NCT00311298 Phase 3
26 TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis Completed NCT00023335 Phase 3 Rifapentine;Isoniazid
27 Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis Completed NCT01517022 Phase 3 nicotine replacement therapy
28 Shortening Treatment by Advancing Novel Drugs Completed NCT02342886 Phase 3 Moxifloxacin;PA-824;Pyrazinamide;HRZE (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol combination tablet);HR (rifampicin plus isoniazid combination tablets)
29 Tuberculosis Treatment Shortening Trial Completed NCT00130247 Phase 3 Ethambutol;Isoniazid;Pyrazinamide;Rifampin
30 Vitamin A Therapy for Tuberculosis Completed NCT00057434 Phase 3 multivitamin
31 Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Completed NCT01061593 Phase 3
32 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3 Cholecalciferol;Migliol Placebo Oil
33 The Treatment of Tuberculosis in HIV-Infected Patients Completed NCT00001033 Phase 3 Ethambutol hydrochloride;Isoniazid;Pyrazinamide;Pyridoxine hydrochloride;Levofloxacin;Rifampin
34 High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
35 Treatment Duration for Abdominal Tuberculosis Completed NCT01124929 Phase 3 RNTCP Category I treatment for 6 months;RNTCP Category I treatment for 9months
36 A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients Completed NCT00398996 Phase 3 Early versus intermediate versus late initiation of ART
37 Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries Completed NCT01061151 Phase 3 Zidovudine (ZDV);Nevirapine (NVP): Antepartum Mothers;Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail;Lamivudine-Zidovudine (3TC-ZDV);Lopinavir-ritonavir (LPV-RTV);Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]);Nevirapine (NVP): Infant short-course;Nevirapine (NVP): Infant extended
38 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01551758 Phase 3 FF/VI
39 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
40 A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis Recruiting NCT02581527 Phase 3 Rifampicin 1200mg;Rifampicin 1800mg;4FDC
41 TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens Recruiting NCT02410772 Phase 3 rifapentine;rifapentine and moxifloxacin;control
42 Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India Recruiting NCT03152903 Phase 2, Phase 3
43 FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis Recruiting NCT02607449 Phase 3 FS-1;Placebo
44 Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) Recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
45 Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis Recruiting NCT03474198 Phase 2, Phase 3 Rifampicin;Isoniazid;Pyrazinamide;Ethambutol;Linezolid;Clofazimine;Rifapentine;Levofloxacin;Bedaquiline;Rifampicin
46 Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis Recruiting NCT02563327 Phase 3 Rifapentine;Moxifloxacin;Rifampin;Isoniazid;Pyrazinamide;Ethambutol
47 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Recruiting NCT02409290 Phase 3 Regimen A locally-used WHO-approved MDR-TB regimen;Moxifloxacin;Clofazimine;Ethambutol;Pyrazinamide;Isoniazid;Prothionamide;Kanamycin;Levofloxacin;Bedaquiline
48 Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis Active, not recruiting NCT00933790 Phase 3 ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
49 A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis Active, not recruiting NCT02333799 Phase 3 Bedaquiline;PA-824;Linezolid
50 Trial of Vitamin D in HIV Progression Active, not recruiting NCT01798680 Phase 3

Search NIH Clinical Center for Pulmonary Tuberculosis

Cochrane evidence based reviews: tuberculosis, pulmonary

Genetic Tests for Pulmonary Tuberculosis

Anatomical Context for Pulmonary Tuberculosis

MalaCards organs/tissues related to Pulmonary Tuberculosis:

41
Lung, Testes, T Cells, Monocytes, Neutrophil, Whole Blood, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Pulmonary Tuberculosis:

19
Lungs

Publications for Pulmonary Tuberculosis

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 2278)
# Title Authors Year
1
Household fuel use and pulmonary tuberculosis in western Nepal: A case-control study. ( 30317104 )
2019
2
History of Pulmonary Tuberculosis. ( 30454916 )
2019
3
Current Medical Management of Pulmonary Tuberculosis. ( 30454919 )
2019
4
Surgical Resection in the Treatment of Pulmonary Tuberculosis. ( 30454920 )
2019
5
Modern Collapse Therapy for Pulmonary Tuberculosis. ( 30454921 )
2019
6
Cognitive Impairment in Zambians With HIV Infection and Pulmonary Tuberculosis. ( 30531294 )
2019
7
Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. ( 29561179 )
2019
8
Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis. ( 29954353 )
2018
9
IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals. ( 29373577 )
2018
10
Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study. ( 29979738 )
2018
11
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. ( 29402317 )
2018
12
Gastrectomy correlates with increased risk of pulmonary tuberculosis: A population-based cohort study in Taiwan. ( 29979430 )
2018
13
Impact of introducing light-emitting diode fluorescence microscopy services for diagnosis of pulmonary tuberculosis under Revised National Tuberculosis Control Program India. ( 29970769 )
2018
14
Chronic Pulmonary Blastomycosis Mimicking Pulmonary Tuberculosis. ( 29547956 )
2018
15
Pulmonary tuberculosis in a male with silicosis. ( 29960278 )
2018
16
Diagnostic pathways and direct medical costs incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment - Tamil Nadu, India. ( 29414980 )
2018
17
Management challenge: Optic disc granuloma in pulmonary tuberculosis. ( 29380785 )
2018
18
Nutrition Status Among HIV-Positive and HIV-Negative Inpatients with Pulmonary Tuberculosis. ( 29397039 )
2018
19
Ex vivo expansion of alveolar macrophages with Mycobacterium tuberculosis from the resected lungs of patients with pulmonary tuberculosis. ( 29401466 )
2018
20
Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D<sub>3</sub> as host directed therapy. ( 29973153 )
2018
21
Cash interventions to improve clinical outcomes for pulmonary tuberculosis: systematic review and meta-analysis. ( 29962550 )
2018
22
Evaluation of Xpert<sup>Ar</sup><i>Mycobacterium tuberculosis</i>/rifampin in sputum-smear negative and sputum-scarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid. ( 29970767 )
2018
23
Positive outcome of pulmonary tuberculosis associated with extraordinary extensive extrapulmonary tuberculosis in an immunocompetent adult. ( 29900898 )
2018
24
Comparative whole-genome sequence analysis of Mycobacterium tuberculosis isolated from tuberculous meningitis and pulmonary tuberculosis patients. ( 29559684 )
2018
25
T Cell Profile was Altered in Pulmonary Tuberculosis Patients with Type 2 Diabetes. ( 29385117 )
2018
26
Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection. ( 29951049 )
2018
27
Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis. ( 29422548 )
2018
28
Four decades of pulmonary tuberculosis in deceased South African miners: trends and determinants. ( 29934377 )
2018
29
A comparative study of the socio-economic risk factors for pulmonary tuberculosis in the Saharia tribe of Madhya Pradesh, India. ( 29931208 )
2018
30
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial. ( 29954183 )
2018
31
Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia. ( 29447273 )
2018
32
Comparative study of effect of Withania somnifera as an adjuvant to DOTS in patients of newly diagnosed sputum smear positive pulmonary tuberculosis. ( 29933868 )
2018
33
Effects of household bleach on sputum smear microscopy to concentrate acid fast bacilli for the diagnosis of pulmonary tuberculosis. ( 29921388 )
2018
34
Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia. ( 29379307 )
2018
35
Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. ( 29416328 )
2018
36
Screening and identification of potential protein biomarkers for evaluating the efficacy of intensive therapy in pulmonary tuberculosis. ( 29959917 )
2018
37
Parallel Tests Using Culture, Xpert MTB/RIF, and SAT-TB in Sputum Plus Bronchial Alveolar Lavage Fluid Significantly Increase Diagnostic Performance of Smear-Negative Pulmonary Tuberculosis. ( 29973917 )
2018
38
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. ( 29384034 )
2018
39
Large-scale genomic analysis shows association between homoplastic genetic variation in Mycobacterium tuberculosis genes and meningeal or pulmonary tuberculosis. ( 29402222 )
2018
40
An HLA class II locus, previously identified by a genome-wide association study, is also associated with susceptibility to pulmonary tuberculosis in a Chinese population. ( 29933081 )
2018
41
Hypercalcemia and acute pancreatitis in a male patient with acute promyelocytic leukemia and pulmonary tuberculosis. ( 29633729 )
2018
42
Chronic pulmonary aspergillosis after pulmonary tuberculosis. ( 30274995 )
2018
43
Arterial embolization for hemoptysis in patients with chronic pulmonary tuberculosis and in patients with bronchiectasis. ( 30282481 )
2018
44
Prevalence of depression among patients with presumptive pulmonary tuberculosis in Rio de Janeiro, Brazil. ( 30365672 )
2018
45
Pulmonary tuberculosis presenting as diffuse alveolar hemorrhage: Believe it or not. ( 30381561 )
2018
46
Dual role of hypoxia-inducible factor 1 α in experimental pulmonary tuberculosis: its implication as a new therapeutic target. ( 29848058 )
2018
47
Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: A cohort study in Taiwan. ( 30278552 )
2018
48
Identifying lung cancer in patients with active pulmonary tuberculosis. ( 30505526 )
2018
49
Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitis. ( 30427928 )
2018
50
Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report. ( 30425530 )
2018

Variations for Pulmonary Tuberculosis

Expression for Pulmonary Tuberculosis

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family, member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule, endosialin Blood - 3.84 0.000
7 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement component 1, q subcomponent, C chain Blood + 3.56 0.000
11 CR1 complement component (3b/4b) receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit Blood + 3.46 0.000
15 LGALSL lectin, galactoside-binding-like Blood - 3.43 0.000
16 BATF2 basic leucine zipper transcription factor, ATF-like 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Blood + 3.38 0.000
20 NAIP NLR family, apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease type III Blood + 3.26 0.000
23 MVD mevalonate (diphospho) decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine-rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement component (3d/Epstein Barr virus) receptor 2 Blood - 3.21 0.000
27 PRSS33 protease, serine, 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L, 6 Blood + 3.16 0.000
33 CRIP2 cysteine-rich protein 2 Blood - 3.15 0.000
34 C1QB complement component 1, q subcomponent, B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family, member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase, ecto (CD73) Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt-like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 (transmembrane) Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.

Pathways for Pulmonary Tuberculosis

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 HLA-DRB1 HP IFNG IFNGR1 IL10 IL12RB1
2
Show member pathways
13.71 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
3
Show member pathways
13.56 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
4
Show member pathways
13.44 IL10 IL12RB1 IL18 IL2 IL4 TLR2
5
Show member pathways
13.42 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
6
Show member pathways
13.26 HLA-DRB1 IFNG IFNGR1 IL2 IL4 TLR2
7
Show member pathways
13.01 IFNG IFNGR1 IL10 IL18 IL2 MBL2
8
Show member pathways
12.94 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
9 12.85 IFNG IFNGR1 IL12RB1 IL2 IL4
10
Show member pathways
12.82 HLA-DRB1 IFNG IFNGR1 IL18 IL2 IL4
11
Show member pathways
12.66 IFNG IL10 IL12RB1 IL18 IL2 TNF
12 12.63 IFNG IL10 IL2 IL4 TLR2 TLR9
13
Show member pathways
12.61 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
14
Show member pathways
12.57 IFNG IFNGR1 IL2 IL4 TNF
15
Show member pathways
12.48 IFNG IL10 IL2 IL4 TNF
16
Show member pathways
12.48 IFNG IFNGR1 IL10 IL12RB1 IL2 IL4
17
Show member pathways
12.39 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
18
Show member pathways
12.36 IFNG IL2 IL4 TNF
19
Show member pathways
12.35 IFNG IL4 TLR2 TNF
20
Show member pathways
12.34 IFNG IL10 IL18 IL2 IL4 TNF
21
Show member pathways
12.33 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TLR2
22 12.26 IFNG IFNGR1 TLR2 TLR9 TNF
23
Show member pathways
12.25 IL10 IL2 TLR9 TNF
24
Show member pathways
12.25 IFNG IFNGR1 IL4 TLR2 TLR9 TNF
25
Show member pathways
12.15 IFNG IFNGR1 IL10 IL18 IL2 IL4
26
Show member pathways
12.09 IFNG IL4 TLR2 TNF
27 12.07 IFNG IL10 IL2 IL4 TNF
28
Show member pathways
12.07 HLA-DRB1 IFNG IL12RB1 IL18 IL2 IL4
29 12.06 IFNG IL2 IL4 TNF
30 12.04 IL10 IL18 IL4 TNF
31 11.96 IFNG IL10 TLR2 TNF
32 11.96 IFNG IFNGR1 IL10 IL12RB1 IL2
33 11.95 HLA-DRB1 IFNG IL18 TLR2 TNF
34 11.9 HLA-DRB1 IL4 TNF
35 11.86 HLA-DRB1 IFNG IFNGR1 IL10 IL18 TLR2
36
Show member pathways
11.85 IFNG IL2 IL4 TNF
37 11.84 IFNG IFNGR1 IL18
38 11.83 IFNG IL10 IL2 TLR9 TNF
39 11.82 IFNG IL2 IL4
40 11.77 IFNG IL10 IL12RB1 IL18 IL2 IL4
41 11.76 IFNG IL10 IL18 IL2 IL4 TNF
42
Show member pathways
11.69 IFNG IL2 TNF
43
Show member pathways
11.68 IFNG IL2 TNF
44 11.64 HLA-DRB1 IL10 MBL2
45 11.63 IL18 TLR2 TNF
46 11.62 IL10 IL18 IL4 TNF
47 11.61 IFNG IL18 TLR2 TNF
48 11.59 IFNG IL2 TNF
49 11.59 IFNG IL10 IL2 IL4
50
Show member pathways
11.58 IFNG IFNGR1 TNF

GO Terms for Pulmonary Tuberculosis

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 HP IFNG IL10 IL18 IL2 IL4
2 external side of plasma membrane GO:0009897 9.55 ADA HLA-DRB1 IL12RB1 P2RX7 TNF
3 extracellular space GO:0005615 9.32 ADA HP IFNG IL10 IL18 IL2

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 IFNG IL2 P2RX7 TNF
2 response to lipopolysaccharide GO:0032496 9.98 IL10 P2RX7 SLC11A1 TLR2
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 IL18 TLR2 TLR9 TNF
4 inflammatory response GO:0006954 9.95 IL10 IL18 P2RX7 SLC11A1 TLR2 TLR9
5 defense response to bacterium GO:0042742 9.93 HP IL10 MBL2 SLC11A1 TLR9 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.89 MBL2 P2RX7 TLR2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.88 IL18 P2RX7 TNF
8 response to organic substance GO:0010033 9.88 HP IL10 P2RX7 TNF
9 interferon-gamma-mediated signaling pathway GO:0060333 9.87 HLA-DRB1 IFNG IFNGR1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IFNG IL18 IL2 IL4
11 interleukin-12-mediated signaling pathway GO:0035722 9.84 IFNG IL10 IL12RB1
12 extrinsic apoptotic signaling pathway GO:0097191 9.84 IFNG P2RX7 TNF
13 positive regulation of interleukin-6 production GO:0032755 9.84 P2RX7 TLR2 TLR9 TNF
14 positive regulation of phagocytosis GO:0050766 9.82 MBL2 SLC11A1 TNF
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.82 IL18 TLR2 TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.81 IL18 TLR2 TLR9 TNF
17 negative regulation of interleukin-6 production GO:0032715 9.8 IL10 TLR9 TNF
18 positive regulation of cytokine secretion GO:0050715 9.8 IL10 P2RX7 TNF
19 cytokine-mediated signaling pathway GO:0019221 9.8 IFNGR1 IL10 IL12RB1 IL18 IL2 IL4
20 positive regulation of interleukin-8 production GO:0032757 9.79 TLR2 TLR9 TNF
21 positive regulation of activated T cell proliferation GO:0042104 9.79 IL12RB1 IL18 IL2
22 positive regulation of interleukin-12 production GO:0032735 9.77 IFNG TLR2 TLR9
23 positive regulation of inflammatory response GO:0050729 9.77 IL18 IL2 TLR2 TLR9 TNF
24 positive regulation of chemokine production GO:0032722 9.75 TLR2 TLR9 TNF
25 positive regulation of T cell differentiation GO:0045582 9.74 ADA IL2 IL4
26 positive regulation of B cell proliferation GO:0030890 9.73 ADA IL2 IL4 TLR9
27 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.72 TLR2 TLR9
28 positive regulation of interleukin-17 production GO:0032740 9.72 IL18 IL2
29 regulation of cytokine secretion GO:0050707 9.72 TLR2 TLR9
30 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.72 IFNG IFNGR1
31 negative regulation of growth of symbiont in host GO:0044130 9.72 IL10 MBL2 TNF
32 I-kappaB phosphorylation GO:0007252 9.71 TLR2 TLR9
33 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.71 IL18 TLR9
34 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR9 TNF
35 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL2 IL4
36 positive regulation of T-helper 1 type immune response GO:0002827 9.71 IL12RB1 SLC11A1
37 T-helper 1 type immune response GO:0042088 9.7 HLA-DRB1 IL18
38 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
39 response to molecule of bacterial origin GO:0002237 9.7 IL10 TLR2 TLR9
40 negative regulation of interleukin-8 production GO:0032717 9.69 IL10 TLR9
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL10 IL4
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
43 positive regulation of neuroinflammatory response GO:0150078 9.68 IL18 TNF
44 positive regulation of tissue remodeling GO:0034105 9.68 IL18 IL2
45 positive regulation of interleukin-18 production GO:0032741 9.67 TLR2 TLR9
46 tumor necrosis factor production GO:0032640 9.67 TLR2 TLR9
47 positive regulation of toll-like receptor signaling pathway GO:0034123 9.65 TLR2 TLR9
48 regulation of isotype switching GO:0045191 9.65 IL10 IL4
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 IFNG TNF
50 receptor biosynthetic process GO:0032800 9.63 IL10 TNF

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 INHA
2 cytokine activity GO:0005125 9.17 IFNG IL10 IL18 IL2 IL4 INHA
3 signaling pattern recognition receptor activity GO:0008329 9.16 TLR2 TLR9

Sources for Pulmonary Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....